ADVERTISEMENT

Comments?
Help us improve Portfolio Grader.


Comments?
Help us improve Portfolio Grader.


Blue Chip Growth

Stock Report: "Pain Therapeutics, Inc." (PTIE) Report Updated: Mar 18, 2017 | Print This Page

Get more stock ratings by Louis Navellier

"Pain Therapeutics, Inc." (PTIE)

Rating: Sell Volatility: Aggressive
Total Grade: D Industry: Pharmaceuticals
Competitors: HSKA,CPIX,ASMB,AKAO

Stock Analysis

Rating: Monthly View

A
B
C
D
F
March April May June July August September October November December January February

Rating: Weekly View

This Week: D down upgrade
Last Week: F same upgrade
Two Weeks Ago: N up no change
service keys

"Pain Therapeutics, Inc."© quotemedia

Company Profile

Pain Therapeutics, Inc., a biopharmaceutical company, develops novel drugs in the United States. The company’s lead drug candidate is REMOXY, an extended-release oral formulation of oxycodone for the management of moderate-to-severe pain when a continuous and around-the-clock opioid analgesic is needed. It also develops abuse-resistant formulation of hydromorphone; and FENROCK, a proprietary abuse-deterrent transdermal pain patch for pain relief. The company has strategic alliance with Pfizer, Inc. to develop and commercialize REMOXY. Pain Therapeutics, Inc. was founded in 1998 and is based in Austin, Texas.